Michael Koslowski
Algemeen Directeur bij Kling Biotherapeutics BV
Profiel
Michael Koslowski is currently the Chief Executive Officer at Kling Biotherapeutics BV since 2022.
Prior to this, he worked as the Chief Medical Officer and Head of R&D at Gammadelta Therapeutics Ltd.
Dr. Koslowski holds a doctorate degree from Universität zu Köln and an undergraduate degree from Universität des Saarlandes.
Actieve functies van Michael Koslowski
| Bedrijven | Functie | Begin |
|---|---|---|
Kling Biotherapeutics BV
 Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Algemeen Directeur | 12-12-2022 |
Eerdere bekende functies van Michael Koslowski
| Bedrijven | Functie | Einde |
|---|---|---|
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Michael Koslowski
| Universität des Saarlandes | Undergraduate Degree |
| Universität zu Köln | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Kling Biotherapeutics BV
Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
